<table border="single" id="id_4c5a679e-01fc-4644-a286-f5c973443f09" width="479.000" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption id="id_d49c285c-ef03-4f6a-b79d-b9833b2b42bf">Table 7. Established and Other Potentially Significant Drug Interactions: Alteration in Dose or Regimen May Be Recommended Based on Drug Interaction Studies or Predicted Interaction</caption>
<col width="24.6%"></col>
<col width="26.3%"></col>
<col width="49.1%"></col>
<tbody>
<tr id="id_892f86be-4f60-4e2e-82b4-01398b0e613b">
<td align="center" stylecode="Botrule Toprule Rrule Lrule" valign="bottom">
<paragraph>Concomitant Drug Class: </paragraph>Drug Name</td>
<td align="center" stylecode="Botrule Rrule" valign="bottom">Effect on Concentration of Delavirdine or Concomitant Drug</td>
<td align="center" stylecode="Botrule Rrule" valign="bottom">Clinical Comment</td>
</tr>
<tr id="id_93418ae3-12ab-4c23-b964-a98c69fedc61">
<td align="center" colspan="3" stylecode="Lrule Botrule Rrule" valign="top">HIV-Antiviral Agents</td>
</tr>
<tr id="id_9fd4487c-f082-46f6-ad59-158743d348aa">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">Amprenavir</td>
<td align="left" stylecode="Botrule Rrule" valign="top">↑Amprenavir</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Appropriate doses of this combination with respect to safety, efficacy, and pharmacokinetics have not been established.</td>
</tr>
<tr id="id_f8d32558-01b0-4501-a37d-e8953a0e0baf">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">Didanosine<sup>a</sup>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">
<paragraph>↓Delavirdine</paragraph>↓Didanosine</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Administration of didanosine (buffered tablets) and RESCRIPTOR should be separated by at least 1 hour.</td>
</tr>
<tr id="id_0c2674cf-2616-4a33-8758-7b47a0ffaf70">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">Indinavir<sup>a</sup>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">↑Indinavir</td>
<td align="left" stylecode="Botrule Rrule" valign="top">A dose reduction of indinavir to 600 mg 3 times daily should be considered when RESCRIPTOR and indinavir are coadministered.</td>
</tr>
<tr id="id_8f31b811-b899-413d-ab92-bd6b2bf3e089">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">Lopinavir/Ritonavir</td>
<td align="left" stylecode="Botrule Rrule" valign="top">
<paragraph>↑Lopinavir</paragraph>↑Ritonavir</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Appropriate doses of this combination with respect to safety, efficacy, and pharmacokinetics have not been established.</td>
</tr>
<tr id="id_17aadc38-e88b-4fce-984e-32c9a18685db">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">Nelfinavir<sup>a</sup>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">
<paragraph>↑Nelfinavir</paragraph>↓Delavirdine</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Appropriate doses of this combination with respect to safety, efficacy, and pharmacokinetics have not been established. (See CLINICAL PHARMACOLOGY: Tables 1 and 2.)</td>
</tr>
<tr id="id_a831ae5d-33a5-4921-9c81-65f67e80300f">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">Ritonavir</td>
<td align="left" stylecode="Botrule Rrule" valign="top">↑Ritonavir</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Appropriate doses of this combination with respect to safety, efficacy, and pharmacokinetics have not been established.</td>
</tr>
<tr id="id_6a2741bb-2761-4ac5-808d-b9a15085c2ac">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">
<paragraph>Saquinavir<sup>a</sup>
</paragraph>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">
<paragraph>↑Saquinavir</paragraph>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">A dose reduction of saquinavir (soft gelatin capsules) may be considered when RESCRIPTOR and saquinavir are coadministered (see CLINICAL PHARMACOLOGY: Table 1). Appropriate doses with respect to safety, efficacy, and pharmacokinetics have not been established.</td>
</tr>
<tr id="id_633c63c4-150e-485a-9df7-8540178a4ad5">
<td align="center" colspan="3" stylecode="Lrule Botrule Rrule" valign="top">Other Agents</td>
</tr>
<tr id="id_517411b4-0684-4b85-9781-e12108582c86">
<td align="left" rowspan="2" stylecode="Lrule Botrule Rrule" valign="top">
<paragraph>
<content stylecode="bold">Acid blockers:</content>
</paragraph>
<paragraph>Antacids<sup>a</sup>
</paragraph>
</td>
<td align="left" rowspan="2" stylecode="Botrule Rrule" valign="top">↓Delavirdine</td>
<td align="left" stylecode="Rrule" valign="top">Doses of an antacid and RESCRIPTOR should be separated by at least 1 hour, because the absorption of delavirdine is reduced when coadministered with antacids.</td>
</tr>
<tr id="id_47eafd19-01f9-4414-89cd-be911d227eb7">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top"></td>
</tr>
<tr id="id_2ff037aa-fdbe-4d03-bfa0-3c81f6fba7d4">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">
<paragraph>
<content stylecode="bold">Histamine H<sub>2</sub>-receptor antagonists:</content>
</paragraph>
<paragraph>Cimetidine, famotidine, nizatidine, ranitidine</paragraph>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">↓Delavirdine</td>
<td align="left" stylecode="Botrule Rrule" valign="top">These agents increase gastric pH and may reduce the absorption of delavirdine. Although the effect of these drugs on delavirdine absorption has not been evaluated, chronic use of these drugs with RESCRIPTOR is not recommended.</td>
</tr>
<tr id="id_3774e45c-edb8-4927-a6ff-b9ba608d85cc">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">
<paragraph>
<content stylecode="bold">Proton pump inhibitors:</content>
</paragraph>Omeprazole, lansoprazole </td>
<td align="left" stylecode="Botrule Rrule" valign="top">↓Delavirdine</td>
<td align="left" stylecode="Botrule Rrule" valign="top">These agents increase gastric pH and may reduce the absorption of delavirdine. Although the effect of these drugs on delavirdine absorption has not been evaluated, chronic use of these drugs with RESCRIPTOR is not recommended.</td>
</tr>
<tr id="id_0504f414-3c47-4824-8c34-4fde7d24f9f6">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">
<content stylecode="bold">Amphetamines</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">↑Amphetamines</td>
<td align="left" stylecode="Botrule Rrule" valign="top">
<paragraph>Use with caution.</paragraph>
</td>
</tr>
<tr id="id_5a0df809-7fdf-4097-89bc-908cf2e03b1b">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">
<paragraph>
<content stylecode="bold">Antidepressant: </content>
</paragraph>Trazodone</td>
<td align="left" stylecode="Botrule Rrule" valign="top">↑Trazodone</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Concomitant use of trazodone and RESCRIPTOR may increase plasma concentrations of trazodone. Adverse events of nausea, dizziness, hypotension, and syncope have been observed following coadministration of trazodone and ritonavir. If trazodone is used with a CYP3A4 inhibitor such as RESCRIPTOR, the combination should be used with caution and a lower dose of trazadone should be considered.</td>
</tr>
<tr id="id_8246b0b9-07d2-475b-aebc-44daa5ae408d">
<td align="left" stylecode="Lrule Rrule" valign="top">
<paragraph>
<content stylecode="bold">Antiarrhythmics:</content>
</paragraph>Bepridil</td>
<td align="left" stylecode="Rrule" valign="top">↑Antiarrhythmics</td>
<td align="left" stylecode="Rrule" valign="top">Use with caution. Increased bepridil exposure may be associated with life-threatening reactions such as cardiac arrhythmias.</td>
</tr>
<tr id="id_53d03597-47f3-449f-aa21-a3342c8b5ec4">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">Amiodarone,lidocaine (systemic), quinidine, flecainide, propafenone</td>
<td align="left" stylecode="Botrule Rrule" valign="top"></td>
<td align="left" stylecode="Botrule Rrule" valign="top">Caution is warranted and therapeutic concentration monitoring is recommended, if available, for antiarrhythmics when coadministered with RESCRIPTOR.</td>
</tr>
<tr id="id_34a6c478-30ba-4cfe-9b7d-3b81b5f6ce6a">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">
<paragraph>
<content stylecode="bold">Anticoagulant:</content>
</paragraph>Warfarin</td>
<td align="left" stylecode="Botrule Rrule" valign="top">↑Warfarin</td>
<td align="left" stylecode="Botrule Rrule" valign="top">It is recommended that INR (international normalized ratio) be monitored.</td>
</tr>
<tr id="id_e3b53de3-b64a-4069-9797-972e1af4b481">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">
<paragraph>
<content stylecode="bold">Anti-infective:</content>
</paragraph>Clarithromycin<sup>a</sup>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">
<paragraph>↑Clarithromycin</paragraph>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">
<paragraph>When coadministered with RESCRIPTOR, clarithromycin should be adjusted in patients with impaired renal function:</paragraph>
<list listtype="unordered">
<item>For patients with CL<sub>CR</sub> 30 to 60 mL/min the dose of clarithromycin should be reduced by 50%.</item>
<item>For patients with CL<sub>CR</sub> &lt;30 mL/min the dose of clarithromycin should be reduced by 75%.</item>
</list>
</td>
</tr>
<tr id="id_44adc2c9-0273-42ce-94b9-061c9829c2e8">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">
<paragraph>
<content stylecode="bold">Calcium channel blockers:</content>
</paragraph>Amlodipine, diltiazem, felodipine, isradipine, nifedipine, nicardipine, nimodipine, nisoldipine, verapamil</td>
<td align="left" stylecode="Botrule Rrule" valign="top">↑Calcium channel blockers</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Caution is warranted and clinical monitoring of patients is recommended.</td>
</tr>
<tr id="id_83be7d9f-2f23-483d-b825-6556f8668027">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">
<content stylecode="bold">Corticosteroid:</content> Dexamethasone</td>
<td align="left" stylecode="Botrule Rrule" valign="top">↓Delavirdine</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Use with caution. RESCRIPTOR may be less effective due to decreased delavirdine plasma concentrations in patients taking these agents concomitantly.</td>
</tr>
<tr id="id_f5000a16-ba8a-4026-acf6-8e2a3ef3faf4">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">
<paragraph>
<content stylecode="bold">Erectile dysfunction agents:</content>
</paragraph>Sildenafil</td>
<td align="left" stylecode="Botrule Rrule" valign="top">↑Sildenafil</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Sildenafil should not exceed a maximum single dose of 25 mg in a 48-hour period.</td>
</tr>
<tr id="id_e94b4f2c-5acd-4f80-9093-6e365f370cb1">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">
<paragraph>
<content stylecode="bold">HMG-CoA reductase inhibitors:</content>
</paragraph>Atorvastatin, cerivastatin, fluvastatin</td>
<td align="left" stylecode="Botrule Rrule" valign="top">
<paragraph>↑Atorvastatin</paragraph>
<paragraph>↑Cerivastatin</paragraph>↑Fluvastatin</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Use lowest possible dose of atorvastatin or cerivastatin, or fluvastatin with careful monitoring, or consider other HMG-CoA reductase inhibitors such as pravastatin in combination with RESCRIPTOR.</td>
</tr>
<tr id="id_592030a1-2616-4126-b9c8-a5717332e32b">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">
<paragraph>
<content stylecode="bold">Immunosuppressants:</content>
</paragraph>
<paragraph>Cyclosporine, </paragraph>tacrolimus, rapamycin</td>
<td align="left" stylecode="Botrule Rrule" valign="top">↑Immunosuppressants</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Therapeutic concentration monitoring is recommended for immunosuppressant agents when coadministered with RESCRIPTOR.</td>
</tr>
<tr id="id_43803ef0-9cc3-41e2-aa64-2e823a1506e0">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">
<content stylecode="bold">Inhaled/nasal steroid:</content> Fluticasone</td>
<td align="left" stylecode="Botrule Rrule" valign="top">↑Fluticasone</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Concomitant use of fluticasone propionate and RESCRIPTOR may increase plasma concentrations of fluticasone propionate. Use with caution. Consider alternatives to fluticasone propionate, particularly for long-term use.</td>
</tr>
<tr id="id_c57352a3-3bee-4a0c-8160-fa9e6f56b29e">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">
<paragraph>
<content stylecode="bold">Narcotic analgesic:</content>
</paragraph>Methadone</td>
<td align="left" stylecode="Botrule Rrule" valign="top">↑Methadone</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Dosage of methadone may need to be decreased when coadministered with RESCRIPTOR.</td>
</tr>
<tr id="id_10d2e44b-291a-497d-988e-0b317f6e62d5">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">
<paragraph>
<content stylecode="bold">Oral contraceptives: </content>
</paragraph>Ethinyl estradiol</td>
<td align="left" stylecode="Rrule" valign="top">↑Ethinyl estradiol</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Concentrations of ethinyl estradiol may increase. However, the clinical significance is unknown.</td>
</tr>
</tbody>
</table>